Primary Biliary Cholangitis
Primary biliary cholangitis (PBC), previously called primary biliary cirrhosis, is a chronic disease in which the bile ducts in the liver are slowly destroyed.
Investigators
Open Research Studies for Primary Biliary Cholangitis
Zydus PBC
Enrolling: Yes
Principle Investigator: Raj Vuppalanchi, MD
Duration: 26 weeks
Patient Population: Non-cirrhotic
Drug(s): Oral Saroglitazar
Interested in this study? Please contact the clinical liver research team: iuliverr@iu.edu
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2b/3 Study to Evaluate the Efficacy and Safety of Saroglitazar Magnesium in Subjects with Primary Biliary Cholangitis
Enrolling: Yes
Principle Investigator: Raj Vuppalanchi, MD
Duration: 59 weeks
Patient Population: Patients diagnosed with PBC
Drug(s): Saroglitazar Magnesium
Interested in this study? Please contact the clinical liver research team: iuliverr@iu.edu
Closed Primary Biliary Cholangitis Studies
Enrolling: No
Principle Investigator: Raj Vuppalanchi, MD
Duration: Upwards 6 - 8 years.
Patient Population: PBC with total Bili > ULN and ≤3x ULN or ALP >5x ULN
Drug(s): Obeticholic Acid tablet or placebo
Enrolling: No
Principle Investigator: Craig Lammert, MD
Duration: 1 visit
Patient Population: PBC/Pre-Transplant and history of no/minimal itch or severe itch.
Enrolling: No
Principle Investigator: Raj Vuppalanchi, MD
Duration: 21 weeks
Patient Population: Patients with moderate to severe itching.
Drug(s): Oral CR845